On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia (Q73514183)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

acute lymphocytic leukemia

4 November 2019

main subject

1 reference

childhood acute lymphocytic leukemia

inferred from title

1 reference

1 reference

H Seidel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

R Nygaard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P J Moe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

G Jacobsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

B Lindqvist

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Slørdal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 May 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

429-434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions.

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Patient characteristics associated with high-risk methotrexate concentrations and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

MTX clearance is more important for intermediate-risk ALL.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Methotrexate pharmacokinetics and prognosis in osteosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

PharmCalc: program for the calculation of clinical pharmacokinetic parameters of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

High-dose methotrexate: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900127-0

7 January 2021

10.1016/S0145-2126(96)00127-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9225071%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference